甲状腺眼病泪腺表现的治疗缓解策略
甲状腺眼病(TED)可累及泪腺系统,出现眼干、畏光、流泪等症状,易被误诊为干眼症、慢性结膜炎或过敏。本文综述了非侵入性支持治疗、药物(糖皮质激素、生物制剂)及手术(眶减压、眼睑修复)等干预措施,强调多学科协作可减少误诊并改善生活质量。
要点
- TED泪腺症状易误诊为干眼症、结膜炎或过敏,需警惕。
- 治疗包括支持治疗、抗炎药物、生物制剂及手术干预。
- 多学科协作可减少误诊并改善患者生活质量。
核心结论
- 多种治疗选择可用于缓解TED的泪腺系统功能障碍。
- 轻度TED患者可从针对症状缓解的支持治疗中获益。
- 多学科协作管理泪腺异常可减少TED相关泪液功能不全的负面影响。
研究设计与样本
- 本文为面向患者的治疗策略综述,描述TED泪腺表现的治疗干预。
主要发现
- 泪腺系统功能障碍源于免疫细胞浸润腺体组织及眼睑 draping 不良导致眼表过度暴露。
- 非侵入性治疗包括局部支持措施、全身和局部糖皮质激素及生物制剂。
- 手术干预包括眶减压和眼睑修复,可减轻突眼和眼睑 draping 不良对角膜暴露的影响。
- 非医疗干预包括戒烟和患者教育。
临床怎么用
- 对TED患者应评估泪腺症状,避免误诊为干眼症、慢性结膜炎或过敏。
- 根据病情选择支持治疗、抗炎药物、生物制剂或手术干预。
- 推荐多学科协作管理TED泪腺异常。
- 建议患者戒烟并接受教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid eye disease (TED) is an autoimmune disease involving periocular and orbital tissue. The manifestations of TED include proptosis, diplopia, visual disturbance, and lacrimal symptoms. Dry/gritty eyes, light sensitivity, and tearing are prominent lacrimal system-related symptoms. They can be misdiagnosed as dry eye syndrome, chronic conjunctivitis, or allergies. Multiple therapeutic interventions can be utilized in the management of lacrimal symptoms of TED. EVIDENCE DESCRIPTION: Lacrimal system dysfunction occurs from immune cell infiltration of glandular tissues as well as from poor eyelid draping causing excess exposure of the globe surface. Noninvasive treatments for lacrimal system abnormalities include local supportive measures aimed at preserving eye surface tear film, systemic and topical medications such as corticosteroids which target inflammation, and biologicals which modify immune responses. Surgical interventions can mitigate the negative impact of proptosis and poor eyelid draping on corneal exposure. These procedures include orbital decompression and eyelid repair. Nonmedical interventions include smoking cessation and patient education. Multidisciplinary care can reduce misdiagnoses, improve management, and reduce the negative impact on quality of life from TED. CONCLUSION: Several treatment options are currently available to mitigate lacrimal system dysfunction in TED. More targeted therapies are emerging or have recently appeared in the clinic. Patients with mild TED can benefit from supportive care aimed at symptomatic relief. An inter-disciplinary approach to managing patients with lacrimal system abnormalities can minimize the negative impact of lacrimal insufficiency associated with TED.
引用
- Reinhardt C, Fotovat N, Siddiqui O, et al. Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease. J Clin Endocrinol Metab. 2026. PMID: 41649397. doi:10.1210/clinem/dgag045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。